On June 24, WuXi XDC rose 3.05% in regular trading, trading at HK$50.75/share, with turnover of HK$23.62 million. This marks the third consecutive trading day of gains for the stock, which has climbed from HK$47.36 on June 18.

On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top pick among leading players in high-growth biotech tracks with attractive valuations. Meanwhile, CMB International also recommended the stock, noting the innovative drug and medical device export trend remains intact and that biomedical has been positioned as a pillar industry. Additionally, subsidiary Dongyao Pharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16 to deliver 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.

Within the Life Sciences Tools and Services sector, the overall sector strengthened. Among individual stocks, Genscript Biotech up 5.24%, WuXi AppTec up 3.82%, WuXi Biologics up 1.73%, forming broad sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)